Zelgen Pharmaceuticals’ ZG006 for injection in combination with PD-1/PD-L1 immune checkpoint inhibitors approved for clinical trials
April 23, 2025
Source: drugdu
47
On the evening of April 20, Zejing Pharmaceutical announced that the combination of ZG006 for injection and PD-1/PD-L1 immune checkpoint inhibitors has obtained the approval notice for drug clinical trials. The announcement shows that the company recently received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and the clinical trial of ZG006 for injection combined with PD-1/PD-L1 immune checkpoint inhibitors for small cell lung cancer has been approved.
The announcement shows that ZG006 for injection is a trispecific antibody drug developed by the company and its subsidiary Gensun Biopharma Inc. through its bi-/multi-specific antibody research and development platform. The drug has obtained clinical trial approval from both the U.S. FDA and China's NMPA, and has been granted orphan drug status by the U.S. FDA.
https://finance.eastmoney.com/a/202504213382407847.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Yahong Pharmaceutical’s loss in the first quarter widened to 83.53 million yuan May 1, 2025
- Fosun Pharma changes its leader! Taking over from Wu Yifang, Chen Yuqing becomes the chairman of Fosun Pharma May 1, 2025
- Tiankang Bio plans to list its animal vaccine business separately on the Beijing Stock Exchange May 1, 2025
- Kangle Guard’s operating income in 2024 fell by 50.2%, and its losses expanded to 357 million yuan May 1, 2025
- Stem cell therapy leads the transformation of Japanese medicine April 30, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
